FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226342685> ?p ?o ?g. }

• W4226342685 endingPage "6134" @default.
• W4226342685 startingPage "6124" @default.
• W4226342685 abstract "Abstract Purpose: Tafasitamab, an Fc-modified, humanized, anti-CD19 monoclonal antibody, in combination with lenalidomide, demonstrated efficacy in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), in the single-arm, phase II L-MIND study (NCT02399085). RE-MIND, a retrospective observational study, generated a historic control for L-MIND to delineate the contribution of tafasitamab to the efficacy of the combination. Patients and Methods: Data were retrospectively collected from patients with R/R DLBCL treated with lenalidomide monotherapy for comparison with tafasitamab + lenalidomide–treated patients (L-MIND). Key eligibility criteria were aligned with L-MIND. Estimated propensity score–based Nearest Neighbor 1:1 Matching methodology balanced the cohorts for nine prespecified prognostic baseline covariates. The primary endpoint was investigator-assessed best overall response rate (ORR). Secondary endpoints included complete response (CR) rate, progression-free survival (PFS), and overall survival (OS). Results: Data from 490 patients going through lenalidomide monotherapy were collected; 140 qualified for matching with the L-MIND cohort. The primary analysis included 76 patients from each cohort who received a lenalidomide starting dose of 25 mg/day. Cohort baseline covariates were comparable. A significantly better ORR of 67.1% (95% confidence interval, 55.4–77.5) was observed for the combination therapy versus 34.2% (23.7–46.0) for lenalidomide monotherapy [odds ratio, 3.89 (1.90–8.14); P &lt; 0.0001]. Higher CR rates were achieved with combination therapy compared with lenalidomide monotherapy [39.5% (28.4–51.4) vs. 13.2% (6.5–22.9)]. Survival endpoints favored combination therapy. Lenalidomide monotherapy outcomes were similar to previously published data. Conclusions: RE-MIND enabled the estimation of the additional treatment effect achieved by combining tafasitamab with lenalidomide in patients with R/R DLBCL." @default.
• W4226342685 created "2022-05-05" @default.
• W4226342685 creator A5006362345 @default.
• W4226342685 creator A5007316044 @default.
• W4226342685 creator A5007938116 @default.
• W4226342685 creator A5020586738 @default.
• W4226342685 creator A5043178404 @default.
• W4226342685 creator A5044284041 @default.
• W4226342685 creator A5046261996 @default.
• W4226342685 creator A5049019689 @default.
• W4226342685 creator A5050866878 @default.
• W4226342685 creator A5053058862 @default.
• W4226342685 creator A5054420604 @default.
• W4226342685 creator A5058320427 @default.
• W4226342685 creator A5061713890 @default.
• W4226342685 creator A5063789179 @default.
• W4226342685 creator A5079925922 @default.
• W4226342685 creator A5082819090 @default.
• W4226342685 creator A5085365536 @default.
• W4226342685 creator A5086354986 @default.
• W4226342685 date "2021-08-25" @default.
• W4226342685 modified "2023-10-13" @default.
• W4226342685 title "RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma" @default.
• W4226342685 cites W1975428611 @default.
• W4226342685 cites W2036193982 @default.
• W4226342685 cites W2096764404 @default.
• W4226342685 cites W2103563361 @default.
• W4226342685 cites W2107894877 @default.
• W4226342685 cites W2109440389 @default.
• W4226342685 cites W2126772526 @default.
• W4226342685 cites W2133201432 @default.
• W4226342685 cites W2138874270 @default.
• W4226342685 cites W2145785161 @default.
• W4226342685 cites W2153558008 @default.
• W4226342685 cites W2559431510 @default.
• W4226342685 cites W2605009867 @default.
• W4226342685 cites W2729210473 @default.
• W4226342685 cites W2744261860 @default.
• W4226342685 cites W2773804840 @default.
• W4226342685 cites W2792232222 @default.
• W4226342685 cites W2891571059 @default.
• W4226342685 cites W2903062212 @default.
• W4226342685 cites W2921072067 @default.
• W4226342685 cites W2931257958 @default.
• W4226342685 cites W2981307194 @default.
• W4226342685 cites W2984927918 @default.
• W4226342685 cites W2989466518 @default.
• W4226342685 cites W3026000147 @default.
• W4226342685 cites W3034162969 @default.
• W4226342685 cites W3112732938 @default.
• W4226342685 cites W4205736005 @default.
• W4226342685 doi "https://doi.org/10.1158/1078-0432.ccr-21-1471" @default.
• W4226342685 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34433649" @default.
• W4226342685 hasPublicationYear "2021" @default.
• W4226342685 type Work @default.
• W4226342685 citedByCount "20" @default.
• W4226342685 countsByYear W42263426852021 @default.
• W4226342685 countsByYear W42263426852022 @default.
• W4226342685 countsByYear W42263426852023 @default.
• W4226342685 crossrefType "journal-article" @default.
• W4226342685 hasAuthorship W4226342685A5006362345 @default.
• W4226342685 hasAuthorship W4226342685A5007316044 @default.
• W4226342685 hasAuthorship W4226342685A5007938116 @default.
• W4226342685 hasAuthorship W4226342685A5020586738 @default.
• W4226342685 hasAuthorship W4226342685A5043178404 @default.
• W4226342685 hasAuthorship W4226342685A5044284041 @default.
• W4226342685 hasAuthorship W4226342685A5046261996 @default.
• W4226342685 hasAuthorship W4226342685A5049019689 @default.
• W4226342685 hasAuthorship W4226342685A5050866878 @default.
• W4226342685 hasAuthorship W4226342685A5053058862 @default.
• W4226342685 hasAuthorship W4226342685A5054420604 @default.
• W4226342685 hasAuthorship W4226342685A5058320427 @default.
• W4226342685 hasAuthorship W4226342685A5061713890 @default.
• W4226342685 hasAuthorship W4226342685A5063789179 @default.
• W4226342685 hasAuthorship W4226342685A5079925922 @default.
• W4226342685 hasAuthorship W4226342685A5082819090 @default.
• W4226342685 hasAuthorship W4226342685A5085365536 @default.
• W4226342685 hasAuthorship W4226342685A5086354986 @default.
• W4226342685 hasBestOaLocation W42263426851 @default.
• W4226342685 hasConcept C126322002 @default.
• W4226342685 hasConcept C141071460 @default.
• W4226342685 hasConcept C143998085 @default.
• W4226342685 hasConcept C17923572 @default.
• W4226342685 hasConcept C203092338 @default.
• W4226342685 hasConcept C2776063141 @default.
• W4226342685 hasConcept C2776364478 @default.
• W4226342685 hasConcept C2778559949 @default.
• W4226342685 hasConcept C2779338263 @default.
• W4226342685 hasConcept C44249647 @default.
• W4226342685 hasConcept C535046627 @default.
• W4226342685 hasConcept C71924100 @default.
• W4226342685 hasConcept C72563966 @default.
• W4226342685 hasConceptScore W4226342685C126322002 @default.
• W4226342685 hasConceptScore W4226342685C141071460 @default.
• W4226342685 hasConceptScore W4226342685C143998085 @default.
• W4226342685 hasConceptScore W4226342685C17923572 @default.
• W4226342685 hasConceptScore W4226342685C203092338 @default.
• W4226342685 hasConceptScore W4226342685C2776063141 @default.

• next